Axl Blockade by BGB324 Inhibits BCR-ABL Tyrosine Kinase Inhibitor-Sensitive and -Resistant Chronic Myeloid Leukemia

被引：33

作者：

Ben-Batalla, Isabel ^{[1
,2
,3
]}

Erdmann, Robert ^{[1
,2
,3
]}

Jorgensen, Heather ^{[4
]}

Mitchell, Rebecca ^{[4
]}

Ernst, Thomas ^{[5
]}

Von Amsberg, Gunhild ^{[1
,2
]}

Schafhausen, Philippe ^{[1
,2
]}

Velthaus, Janna L. ^{[1
,2
,3
]}

Rankin, Stephen ^{[4
]}

Clark, Richard E. ^{[6
]}

Koschmieder, Steffen ^{[7
]}

Schultze, Alexander ^{[1
,2
]}

Mitra, Subir ^{[8
]}

Vandenberghe, Peter ^{[9
]}

Brummendorf, Tim H. ^{[7
]}

Carmeliet, Peter ^{[10
,11
]}

Hochhaus, Andreas ^{[5
]}

Pantel, Klaus ^{[3
]}

Bokemeyer, Carsten ^{[1
,2
]}

Helgason, G. Vignir ^{[12
]}

Holyoake, Tessa L. ^{[4
]}

Loges, Sonja ^{[1
,2
,3
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect BMT, Hamburg, Germany

[2] Univ Med Ctr Hamburg Eppendorf, Univ Comprehens Canc Ctr Hamburg, Hubertus Wald Tumorzentrum, Dept Hematol & Oncol,Sect Pneumol, Hamburg, Germany

[3] Univ Med Ctr Hamburg Eppendorf, Dept Tumor Biol, Ctr Med Expt, Hamburg, Germany

[4] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Paul OGorman Leukaemia Res Ctr, Glasgow, Lanark, Scotland

[5] Jena Univ Hosp, Hematol Oncol, Jena, Germany

[6] Royal Liverpool Univ Hosp, Dept Haematol Mol & Clin Canc Med, Liverpool, Merseyside, England

[7] Rhein Westfal TH Aachen, Dept Hematol Oncol Hemostaseol & Stem Cell Transp, Fac Med, Aachen, Germany

[8] Milton Keynes Hosp NHS Fdn Trust, Dept Haematol, Milton Keynes, Bucks, England

[9] Univ Hosp Leuven, Ctr Human Genet, Leuven, Belgium

[10] VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, Leuven, Belgium

[11] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, Leuven, Belgium

[12] Univ Glasgow, Inst Canc Sci, Coll Med Vet & Life Sci, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland

来源：

CLINICAL CANCER RESEARCH | 2017年 / 23卷 / 09期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; IMATINIB RESISTANCE; BREAST-CANCER; BONE-MARROW; CELLS; GENE; THERAPY; CML; RECOMMENDATIONS; IDENTIFICATION;

D O I：

10.1158/1078-0432.CCR-16-1930

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: BCR-ABL kinase inhibitors are employed successfully for chronic myeloid leukemia (CML) treatment. However, resistant disease and persistence of BCR-ABL1-independent leukemia stem and progenitor cells (LSPC) remain clinical challenges. The receptor tyrosine kinase Axl can mediate survival and therapy resistance of different cancer cells. We investigated the therapeutic potential of Axl inhibition in CML. Experimental Design: We used primary cells from patients with CML and TKI-sensitive and -resistant BCR-ABL1(+) CML cell lines and a novel ponatinib-resistant cell line KCL-22 PonR. We analyzed the effects of genetic and pharmacologic Axl blockade by the small-molecule Axl inhibitor BGB324 in vitro and in vivo. In BCR-ABL1-unmutated cells, we also investigated BGB324 in combination with imatinib. Results: We demonstrate overexpression of Axl receptor tyrosine kinase in primary cells of patients with CML compared with healthy individuals and a further increase of Axl expression in BCR-ABL TKI-resistant patients. We show that Axl blockage decreased growth of BCR-ABL TKIsensitive CML cells including CD34(+) cells and exerts additive effects with imatinib via inhibition of Stat5 activation. BGB324 also inhibits BCR-ABL TKI-resistant cells, including T315I-mutated and ponatinib-resistant primary cells. BGB324 exerted therapeutic effects in BCR-ABL1 T315Imutated and ponatinib-resistant preclinical mouse models. Notably, BGB324 does not inhibit BCR-ABL1 and consequently inhibits CML independent of BCR-ABL1 mutational status. Conclusions: Our data show that Axl inhibition has therapeutic potential in BCR-ABL TKI-sensitive as well as -resistant CML and support the need for clinical trials. (C) 2016 AACR.

引用

页码：2289 / 2300

页数：12

共 50 条

[11] Inhibition of imatinib-mediated apoptosis by the caspase-cleaved form of the tyrosine kinase Lyn in chronic myelogenous leukemia cells [J].